Aspect Announces CEO Leadership Transition and New Independent Board
7.1.2026 00:13:00 CET | Business Wire | Press release
Aspect, a leading provider of cloud-based workforce management solutions, has announced a leadership transition, including the appointment of Jeff Kupietzky as Interim Chief Executive Officer and the formation of a new independent Board of Directors, marking an important next chapter for the company.
As part of this transition, Darryl Kelly will step down as Chief Executive Officer and transition into a Strategic Advisor role, effective January 1, 2026.
Darryl led Aspect through a pivotal period of transformation, helping reposition the business, refine its vision, and reinvigorate its innovation and execution. The company and its stakeholders thank Darryl for his leadership and contributions during a period of meaningful change. With Darryl continuing as Strategic Advisor, the organization retains continuity for employees, customers, and stakeholders.
“Aspect is starting a new season, building upon the strong foundation we’ve created together,” said Darryl Kelly. “This transition is about creating space for the right leadership to carry that vision forward. Our mission and culture remain intact, and I’m excited to see the company continue to grow and go even further.”
With Darryl’s support, the Board has appointed Jeff Kupietzky as Interim CEO while Aspect begins a search for its next permanent leader. Jeff is an experienced software industry executive with a strong track record of guiding enterprise technology companies through periods of transformation and growth. He most recently served as Interim CEO of Glassbox, a digital customer experience analytics provider.
“I’m honored to step in and lead Aspect at this moment,” said Jeff Kupietzky. “Aspect has a strong foundation, a talented team, and a grand vision. I look forward to working closely with the organization to build on that momentum, continue serving our customers and partners, and support the company through this next phase.”
New Independent Board of Directors
In conjunction with the leadership transition, Aspect announced the appointment of a new independent Board of Directors, bringing a combined 90 years of enterprise software, operations, and governance experience:
- Tom Manning (Board Chair) – Tom Manning is the former Chairman and CEO of Dun & Bradstreet and a seasoned global executive with more than 40 years of leadership experience across data, IT services, enterprise software, and outsourcing. He currently serves as Chairman of Cresco Labs, a director of CommScope, and founder of Harvard Square Lab. He holds an MBA from Stanford University and an AB in East Asian Studies with honors from Harvard College.
- Louis Summe – Louis Summe is a tech entrepreneur, best known as the Co-Founder and former CEO of LiveVox (NICE), a cloud contact center platform, bringing over 30 years of experience in developing enterprise customer engagement technology, with early career roots at EDS (HP Enterprise), Merck-Medco (Cigna), and Physicians Online (WebMD). He holds an MBA from Columbia Business School, is based in San Francisco, and also serves as Executive Chairman at VanillaSoft.
- Nicole Anasenes – Nicole Anasenes is a seasoned operational executive with more than 20 years of experience scaling and transforming global technology companies. She has served as CFO and COO at ANSYS, Squarespace, and Infor, leading enterprise transformation, IPO readiness, and SaaS transitions. She currently serves on the boards of Motorola Solutions and Fidelity National Information Services (FIS) as Audit Chair, and holds an MBA from Wharton.
“As we step into Aspect’s next phase, a board that pairs operational rigor with strategic vision is essential,” said Tom Manning, Board Chair. “Nicole, Louis, and I have each scaled and unlocked the potential of mission-critical software companies. We look forward to combining our experience with Aspect’s momentum to accelerate the company’s existing strategies and long-term strategic vision to create value for our customers, partners, and people.”
Continuity and Outlook
Aspect confirms that this leadership transition willnot impact its services, delivery, or commercial agreements that customers, partners, and vendors rely upon. The company remains focused on helping organizations unlock the full potential of their workforce through intelligent, enterprise-grade workforce management solutions.
About Aspect
Aspect is a proven leader in Workforce Management, helping the world’s most complex organizations unlock the full potential of their workforce. Backed by over 50 years of innovation, Aspect delivers enterprise-grade solutions that combine forecasting, scheduling, performance management, and employee engagement into one intelligent platform. Powered by Aspect Intelligence, the platform transforms disconnected workforce data into predictive, actionable insights—enabling faster decisions, stronger teams, and better business outcomes. Trusted by global leaders in financial services, telecommunications, airlines, retail, and more, Aspect helps enterprises adapt in real time, control costs, and deliver exceptional service at scale. Learn more at www.aspect.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260106187555/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom